Elsevier

Journal of Hepatology

Volume 63, Issue 1, July 2015, Pages 174-182
Journal of Hepatology

Research Article
Effect of aerobic exercise training dose on liver fat and visceral adiposity

https://doi.org/10.1016/j.jhep.2015.02.022Get rights and content

Background & Aims

Aerobic exercise reduces liver fat and visceral adipose tissue (VAT). However, there is limited data from randomized trials to inform exercise programming recommendations. This study examined the efficacy of commonly prescribed exercise doses for reducing liver fat and VAT using a randomized placebo-controlled design.

Methods

Inactive and overweight/obese adults received 8 weeks of either; i) low to moderate intensity, high volume aerobic exercise (LO:HI, 50% VO2peak, 60 min, 4 d/week); ii) high intensity, low volume aerobic exercise (HI:LO, 70% VO2peak, 45 min, 3 d/week); iii) low to moderate intensity, low volume aerobic exercise (LO:LO, 50% VO2peak, 45 min, 3 d/week); or iv) placebo (PLA). Liver fat (spectroscopy) and VAT (magnetic resonance imaging) were measured before and after intervention.

Results

Forty-seven of the 48 (n = 12 in each group) participants completed the trial. There were no serious adverse events. There was a significant change in group × time interaction in liver fat, which reduced in HI:LO by 2.38 ± 0.73%, in LO:HI by 2.62 ± 1.00%, and in LO:LO by 0.84 ± 0.47% but not in PLA (increase of 1.10 ± 0.62%) (p = 0.04). There was a significant reduction in VAT in HI:LO (−258.38 ± 87.78 cm3), in LO:HI (−386.80 ± 119.5 cm3), and in LO:LO (−212.96 ± 105.54 cm3), but not in PLA (92.64 ± 83.46 cm3) (p = 0.03). There were no significant differences between the dose or intensity of the exercise regimen and reductions in liver fat or VAT (p >0.05).

Conclusion

The study found no difference in efficacy of liver fat reduction by either aerobic exercise dose or intensity. All of the aerobic exercise regimens employed reduced liver fat and VAT by a small amount without clinically significant weight loss.

Introduction

It is now recognized that the topography of body fat distribution predicts the adverse cardiovascular and metabolic consequences of obesity independent of fat quantity. For instance, high levels of visceral adipose tissue (VAT) are an independent predictor of hypertension [1], myocardial infarction [2], and insulin resistance [3], [4]. Likewise, excess liver fat, as seen in non-alcoholic fatty liver disease (NAFLD), has emerged as an independent risk factor for cardiometabolic disease that may be more strongly associated with risk than VAT [5], [6]. Hence, reducing ectopic fat deposits is a suitable target for interventions to prevent disease.

Since there are limited pharmacological agents to specifically reduce ectopic fat, the efficacy of lifestyle therapies has become a focus of research. In this regard, weight loss via diet and exercise reduces VAT [7], [8] and liver fat [9], [10], [11] but reductions of ⩾3% of body weight are generally required for hepatic benefit, with greater weight loss (5–10%) producing superior benefits [12]. However, these levels of weight loss are inherently difficult to sustain [13]. Given that NAFLD afflicts one third of adults [14] and most obese individuals [15], the efficacy of lifestyle interventions that do not rely on weight loss (such as moderate exercise) warrants investigation.

Several trials have examined the effect of exercise interventions on liver fat, but their interpretation is limited by small sample sizes, lack of non-exercise control groups and heterogeneity in exercise modality and dose. These studies employed exercise doses ranging from 2 to 6 days per week, lasting for 20–60 min per session, with intensities ranging between low (45% VO2peak) and strenuous (85% of VO2peak) [9], [10], [16], [17], [18], [19], [20], [21], [22]. Therefore, establishing practical recommendations for exercise prescription is difficult based on the current evidence.

The purpose of this study was to investigate the efficacy of regular aerobic exercise at one of three doses requiring different levels of effort and time commitment vs. a sham exercise placebo control (PLA) in reducing liver fat and VAT in overweight/obese adults using gold standard, double-blind, randomized placebo-controlled design. We also measured the effects of these interventions on other markers of cardiometabolic risk in order to advise practical recommendations.

Section snippets

Experimental protocol

Intrahepatic lipid (IHL) and abdominal adiposity, including VAT, were assessed before and after 8 weeks of exercise training or PLA intervention. Cardiorespiratory fitness/work capacity, anthropometric measurements (body weight, BMI, and waist circumference), blood lipids, serum aminotransferases, hs-CRP and resting blood pressure were also measured at baseline and post-intervention. The primary aim of the study was assessed by comparing the mean change in liver fat and VAT between the PLA group

Results

One hundred and twenty-two individuals were screened by telephone interview, with 48 eligible volunteers (17 men and 31 women) undergoing initial assessment and randomization (Fig. 1). The study population had an average BMI of 33.4 ± 1.3 kg/m2 and mean age of 43.6 ± 3.0 years. Baseline participant characteristics are described in Table 1. All participants completed the training and PLA interventions. Post-intervention dietary and habitual physical activity data were unavailable for some participants

Discussion

We investigated the effectiveness of commonly prescribed doses of aerobic exercise training compared with a PLA group, independent of dietary intervention or weight loss, on fat distribution including liver fat and VAT in previously inactive adults. We observed a significant reduction in liver fat in all aerobic exercise intervention groups, with the effect size when compared with PLA being large (ES = 1.42, 1.23, and 0.96 for the HI:LO, LO:HI, and LO:LO groups, respectively). These benefits were

Financial support

This research was supported by funding from the Diabetes Australia Research Trust. (Establishment Grant: N.A. Johnson). JG is supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (1053206) and a Project grant (1049857). AS is supported by fellowships from the University of Sydney/Sydney Medical School and the National Health and Medical Research Council. The funding

Conflict of interest

S.E. Keating, D.A. Hackett, H.M. Parker, M.K Baker, V.H. Chuter, H.T. O’Connor, J.A. Gerofi, and A. Sainsbury declare no conflict of interest. N.A. Johnson: has received honoraria for speaking engagements for Merck Sharp & Dohme. I.D. Caterson: has performed and still performs clinical trials of obesity treatment and prevention some of which have been funded by government, but others by the pharmaceutical industry. Current trials are funded by the NHMRC [3], NovoNordisk, Amylin Corporation, the

Authors’ contributions

Study concept and design (JGeorge, NJ), acquisition of data (SK, DH), analysis and interpretation of data (SK, NJ, JGeorge and HP), drafting and critical revision of manuscript (all authors), statistical analysis (SK, NJ). All authors approved the final draft for submission.

References (50)

  • S. Fujioka et al.

    Treatment of visceral fat obesity

    Int J Obes

    (1991)
  • D. Kim et al.

    Nonalcoholic fatty liver disease is associated with coronary artery calcification

    Hepatology

    (2012)
  • E. Fabbrini et al.

    Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity

    Proc Natl Acad Sci U S A

    (2009)
  • R. Ross et al.

    Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial

    Obes Res

    (2004)
  • I. Ismail et al.

    A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat

    Obes Res

    (2012)
  • Y. Tamura et al.

    Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients

    J Clin Endocrinol Metab

    (2005)
  • K. Shah et al.

    Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults

    Obesity

    (2009)
  • S. Schäfer et al.

    Lifestyle intervention in individuals with normal versus impaired glucose tolerance

    Eur J Clin Invest

    (2007)
  • J.D. Browning et al.

    Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

    Hepatology

    (2004)
  • S. Bellentani et al.

    Prevalence of and risk factors for hepatic steatosis in Northern Italy

    Ann Intern Med

    (2000)
  • M.C. Devries et al.

    Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and women

    Obesity

    (2008)
  • F.M. Finucane et al.

    The effects of aerobic exercise on metabolic risk, insulin sensitivity and intrahepatic lipid in healthy older people from the Hertfordshire Cohort Study: a randomised controlled trial

    Diabetologia

    (2010)
  • N.A. Johnson et al.

    Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss

    Hepatology

    (2009)
  • F. Shojaee-Moradie et al.

    Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism

    Diabetologia

    (2007)
  • B.H. Goodpaster et al.

    Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial

    JAMA

    (2010)
  • Cited by (221)

    View all citing articles on Scopus
    View full text